Results 21 to 30 of about 6,976 (185)
The safety of trastuzumab deruxtecan (T‐DXd) in breast cancer brain metastases with a focus on interstitial lung disease/pneumonitis: A systematic review and meta‐analysis [PDF]
CancerAbstract Background Although trastuzumab deruxtecan (T‐DXd) demonstrated unprecedented intracranial efficacy in HER2‐positive breast cancer brain metastases (BCBM), its association with interstitial lung disease (ILD)/pneumonitis posed a critical safety concern in this high‐risk population.
Ma Y, Li X, Jiang Y, Xiao L, Sun T.
europepmc +2 more sources
Breast Cancer: Targets and Therapy, 2021 Anna S Linehan,1 Orla M Fitzpatrick,1 Patrick G Morris1,2 1Cancer Clinical Trials and Research Unit, Beaumont Hospital, Dublin, Ireland; 2Department of Medical Oncology, Royal College of Surgeons in Ireland, Dublin, IrelandCorrespondence: Patrick G ...
Linehan AS, Fitzpatrick OM, Morris PG
doaj
Novel HER2-targeted therapy to overcome trastuzumab resistance in HER2-amplified gastric cancer
Scientific Reports, 2023 Trastuzumab is used to treat HER2-amplified metastatic gastric cancer; however, most patients become trastuzumab-resistant within a year. Knowledge of the mechanisms underlying trastuzumab resistance is required to overcome this limitation.
Juin Park +8 more
doaj +1 more source
Trastuzumab deruxtecan: A quantum leap in HER2-positive breast cancer
Indian Journal of Medical and Paediatric Oncology, 2019 Docetaxel, trastuzumab, and pertuzumab, known as THP, is the preferred first-line treatment for HER2-positive advanced breast cancer, and the second-line drug of choice is trastuzumab emtansine.
Manikandan Dhanushkodi
doaj +1 more source
Опухоли женской репродуктивной системыBackground. Reducing malignant mortality to 185 cases per 100,000 by 2030 is one of goals of the state program “Healthcare development” in Russia.Aim. To assess potential impact of using trastuzumab deruxtecan in patients with breast cancer on reducing ...
N. A. Avxentyev +2 more
doaj +1 more source
Frontiers in Pharmacology, 2022 Background: The DESTINY-Breast03 clinical trial demonstrated that trastuzumab deruxtecan (T-DXd) outperformed trastuzumab emtansine (T-DM1) in progression-free survival (PFS) in patients with human epidermal growth factor receptor 2 (HER2)-positive ...
Jiangping Yang +6 more
doaj +1 more source
Toxicology ReportsThis study provides a detailed pharmacological evaluation of the recently approved antibody-drug conjugates (ADCs), fam-trastuzumab deruxtecan-nxki and sacituzumab govitecan-hziy, focusing on their adverse event (AE) profiles post-approval by the United ...
Amjad Z. Alrosan +4 more
doaj +1 more source
T Cell Exhaustion in Cancer Immunotherapy: Heterogeneity, Mechanisms, and Therapeutic Opportunities
Advanced Science, EarlyView.T cell exhaustion limits immunotherapy efficacy. This article delineates its progression from stem‐like to terminally exhausted states, governed by persistent antigen, transcription factors, epigenetics, and metabolism. It maps the exhaustion landscape in the TME and proposes integrated reversal strategies, providing a translational roadmap to overcome
Yang Yu +7 more
wiley +1 more source
Antibody‐Empowered Nanomedicine for Precise Biomedical Applications
Advanced Science, EarlyView.This review explores strategies for functionalizing nanoparticles with antibodies to construct antibody‐empowered nanomedicine. It discusses the classification of these nanomedicines based on antibody structure, with a specific focus on their biomedical applications in diagnostics, bioimaging, and therapeutics for various diseases.
Chen Chen +7 more
wiley +1 more source
JTO Clinical and Research ReportsHER2 mutations have been identified as potential mechanisms of resistance to EGFR-directed therapies in patients with advanced or metastatic NSCLC. Here, we report the case of a 65-year-old female with metastatic, EGFR exon 19–mutant NSCLC initially ...
Hailey M. Hirata, PharmD +2 more
doaj +1 more source